gp100 (PMEL)
gp100 is a pigment-cell protein, and the target of the first bispecific drug to improve survival in a solid tumour, uveal melanoma.
Tebentafusp (Kimmtrak), an ImmTAC fusing a high-affinity TCR against gp100/HLA-A*02:01 to an anti-CD3 effector, improved overall survival in metastatic uveal melanoma (IMCgp100-202).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · gp100 is a pigment-cell protein, and the target of the first bispecific drug to improve survival in a solid tumour, uveal melanoma.
- 1 · What it is
gp100 is a pigment-cell protein, and the target of the first bispecific drug to improve survival in a solid tumour, uveal melanoma.
- 2 · What goes wrong in cancer
Melanosomal matrix protein; intracellular, presented on HLA.
- 3 · How drugs use it
1 product aims at gp100 (PMEL): bispecific antibodies. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Biology
Melanosomal matrix protein; intracellular, presented on HLA.
- Melanoma including uveal
How common it is, by cancer
Latest papers
topQuery for this target: (TITLE:"gp100" OR ABSTRACT:"gp100" OR TITLE:"PMEL" OR ABSTRACT:"PMEL") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about gp100 (PMEL), not a curated reading list.
Pages like this
not linked directly; found by shared links- TargetPRAME
Shares Uveal melanoma, Antigen presentation & immune editing, TCR-T cell therapy, T-cell engagers (bispecific) and the tag tcr-target.
- TargetMAGE-A4
Shares Antigen presentation & immune editing, TCR-T cell therapy, Melanoma and the tag tcr-target.
- CompanyImmunocore
Shares IMCgp100-202, Oxford Cancer – Oxford University Hospitals and University of Oxford, Tebentafusp, Uveal melanoma.
- TermHLA-A*02:01 restriction
Shares Tebentafusp, Uveal melanoma, Antigen presentation & immune editing, TCR-T cell therapy.
- IdeaTCR therapeutics for non-HLA-A*02 patients
Shares Tebentafusp, TCR-T cell therapy, T-cell engagers (bispecific), Melanoma.
- ProductBrenetafusp
Shares Tebentafusp, Uveal melanoma, T-cell engagers (bispecific), Melanoma.
- IdeaAntibodies that see mutant KRAS and p53 fragments displayed on the cell surface
Shares Tebentafusp, TCR-T cell therapy, T-cell engagers (bispecific).
- IdeaShared splice-derived neoantigens as off-the-shelf vaccine targets
Shares Antigen presentation & immune editing, TCR-T cell therapy, Melanoma.